Lindbrook Capital’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Lindbrook Capital’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-27,800	Closed	-$2.93K	–	2771
2023 Q4	$2.93K	Hold	27,800	–	–	﹤0.01%	2129
2023 Q3	$6.25K	Buy	+27,800	New	+$7.47K	﹤0.01%	1667

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lindbrook Capital's DNA.WS Position: Q1 2024 in Review

Lindbrook Capital sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2024, closing a stake of 27,800 shares — an estimated $2.93K sold.

Lindbrook Capital first reported a position in DNA.WS in Q3 2023 and held it in 2 quarters. The position peaked at $6.25K in Q3 2023. 28 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2024.

Lindbrook Capital reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2024 after selling out during the quarter.
Lindbrook Capital sold 27,800 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2024, an estimated $2.93K.
Lindbrook Capital first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2023 and held it in 2 quarters.
Lindbrook Capital's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $6.25K in Q3 2023.
28 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2024.

Based on Lindbrook Capital's 13F filing for Q1 2024, filed 25 Apr 2024.